In the development of patient-centric injection systems, the consideration points are multifactorial, which would include the drug, primary container, industrial design and branding, as well as end user requirements. These factors could pose a challenge in maintaining the set timelines of the whole combination product development stream. We argue that a flexible design and development model well-integrated through a modular platform device technology can help mitigate project risks and support fast time-to-market.
In this webinar, we discuss a modular platform technology built upon SHL’s Molly® autoinjector. The core Molly technology is designed with integral front and rear subassembly components, resulting in a robust platform that allows for a mix of customizations for industrial design, manufacturing, as well as end user needs. With the rising development of biosimilars not just in the US and Europe – but also in Asia Pacific – a customizable platform to support the distinct and varying requirements of each combination product will be crucial.
Presented by
Lyndon Wild,
Senior Director of Business Development
Lyndon Wild is a Senior Director of Business Development at SHL Medical, leading the organization’s commercial initiatives within the Asia Pacific region. Prior to joining the team, he spearheaded SHL’s complex manufacturing operations for almost four years (2016-2020). Lyndon brings more than 20 years of professional experience in director-level roles within the pharmaceutical, medical device and medical packaging industries.
Sharon Liu,
Senior Manager of Business Development
Sharon Liu is a Senior Manager of Business Development at SHL Medical, managing sales and relationships of key accounts within the APAC region. Prior to joining the commercial team, Sharon led cross-functional teams in medical device product development from initial design through to commercial readiness in Project Management for 8 years (2007-2015).